Trinity Biotech secures lender waiver for liquidity covenant breaches
TRIB•TRIB•TRIB•TRIB•Trinity Biotech entered a fifth credit agreement amendment that conditionally waives minimum liquidity covenant compliance for June through October 2026, including resulting defaults. The amendment also provides for a $96.16 million note to become the Second A&R Note upon effectiveness.
Trinity Biotech entered a fifth credit agreement amendment dated November 6, 2026, with lenders led by administrative agent Perceptive Credit Holdings III. The amendment conditionally waives minimum liquidity covenant compliance for June through October 2026, including resulting defaults; the borrowers reported breaches for June, July and August.
Previous terms required unrestricted cash of $1 million through September 30, rising to $3 million on October 1. An outstanding Amended and Restated Note with original principal of $96.16 million will become the Second A&R Note upon the amendment’s effectiveness.
